IHT Wealth Management’s Protalix BioTherapeutics PLX Stock Holding History

IHT Wealth Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28,800	Closed	-$57.6K	–	1013
2023 Q2	$57.6K	Buy	28,800 +2,000	+7%	+$4.76K	﹤0.01%	947
2023 Q1	$56.3K	Hold	26,800	–	–	﹤0.01%	927
2022 Q4	$36.7K	Buy	26,800 +4,800	+22%	+$5.26K	﹤0.01%	887
2022 Q3	$23K	Hold	22,000	–	–	﹤0.01%	855
2022 Q2	$24K	Sell	22,000 -2,000	-8%	-$2.34K	﹤0.01%	719
2022 Q1	$25K	Hold	24,000	–	–	﹤0.01%	756
2021 Q4	$20K	Sell	24,000 -9,200	-28%	-$9.63K	﹤0.01%	799
2021 Q3	$44K	Buy	+33,200	New	+$50.5K	﹤0.01%	790

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

IHT Wealth Management's PLX Position: Q3 2023 in Review

IHT Wealth Management sold out of Protalix BioTherapeutics (PLX) in Q3 2023, closing a stake of 28,800 shares — an estimated $57.6K sold.

IHT Wealth Management first reported a position in PLX in Q3 2021 and held it in 8 quarters. The position peaked at $57.6K in Q2 2023. 61 funds tracked by Wall St. Rank hold PLX as of Q3 2023.

IHT Wealth Management reported no remaining Protalix BioTherapeutics position as of Q3 2023 after selling out during the quarter.
IHT Wealth Management sold 28,800 Protalix BioTherapeutics shares in Q3 2023, an estimated $57.6K.
IHT Wealth Management first reported a position in Protalix BioTherapeutics in Q3 2021 and held it in 8 quarters.
IHT Wealth Management's Protalix BioTherapeutics position peaked at $57.6K in Q2 2023.
61 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2023.

Based on IHT Wealth Management's 13F filing for Q3 2023, filed 14 Nov 2023.